as 04-03-2025 12:43pm EST
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Founded: | 2001 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 4.7M | IPO Year: | 2006 |
Target Price: | $6.00 | AVG Volume (30 days): | 23.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -19.03 | EPS Growth: | N/A |
52 Week Low/High: | $1.03 - $12.25 | Next Earning Date: | 05-06-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TOVX Breaking Stock News: Dive into TOVX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
GlobeNewswire
15 days ago
ACCESS Newswire
16 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
4 months ago
Associated Press Finance
5 months ago
GlobeNewswire
5 months ago
The information presented on this page, "TOVX Theriva Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.